Harvard Bioscience (HBIO)
NASDAQ:HBIO
Want to see HBIO full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.1Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed but balanced picture: meaningful operational progress and product-led margin improvement (strong NPI momentum, gross margin expansion, pharma sales growth and on-track cost-savings initiatives) were contrasted with near-term revenue pressure, regional softness (Americas and APAC), flat adjusted EBITDA and cash-flow headwinds from inventory builds and financing costs. Management reaffirmed guidance and highlighted multi-year strategic drivers, but near-term financials remain modest.Company Guidance
Revenue in Line with Guidance
Reported Q1 revenue of $20.8M, within guidance of $20.0M–$22.0M. Q2 guidance ($20.5M–$22.5M) midpoint implies ~5% year-over-year growth; company reaffirmed full-year 2026 revenue guidance of +2% to +4%.
Gross Margin Expansion
Adjusted gross margin improved to 59%, up ~300 basis points year-over-year (from ~56% in Q1 2025). Management is targeting consistent gross margins >60% and FY gross margin guidance of 58%–60%.
Strong NPI and Translational Product Momentum
New product innovation (NPI) revenue grew to >12% of total (from ~4% a year ago). The Mesh MEA, BTX and SoHo platforms now represent ~15%–20% of revenue and are expected to deliver double-digit revenue growth for the full year. Sales to pharma and biotech customers grew >20% year-over-year.
Improved Profitability Metrics Versus Prior Year Impairment
GAAP operating loss narrowed to $1.2M versus a $49.7M loss in prior year (prior included a $48M goodwill impairment). Adjusted EBITDA was $0.8M (flat YoY) and adjusted EPS improved to -$0.33 from -$1.25 a year ago.
Operational and Commercial Initiatives
Project Viking (manufacturing consolidation) remains on track and expected to yield $3M in savings in 2027 and $4M annually thereafter. Enhanced distribution with Fisher North America drove high-single-digit sales growth; leadership strengthened with hiring of an experienced SVP of Commercial; Made in China pilot launched for BTX to address local sourcing incentives.
HBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $6.84 | $5.41 | -20.91% |
Mar 17, 2026 | $5.01 | $4.87 | -2.79% |
Nov 06, 2025 | $5.89 | $5.46 | -7.30% |
Aug 11, 2025 | $5.28 | $4.79 | -9.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Harvard Bioscience (HBIO) report earnings?
Harvard Bioscience (HBIO) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Harvard Bioscience (HBIO) earnings time?
Harvard Bioscience (HBIO) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HBIO EPS forecast?
HBIO EPS forecast for the fiscal quarter 2026 (Q2) is -0.21.